Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline

In a report released yesterday, Kostas Biliouris from BMO Capital reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $75.00.

Kostas Biliouris has given his Buy rating due to a combination of factors that highlight the promising potential of Crispr Therapeutics AG. The company’s recent partnership with Sirius to co-develop and co-commercialize SRSD107, a long-acting siRNA targeting FXI, is a significant move. This collaboration is seen as promising because SRSD107 addresses a large market opportunity in the FXI space, which is attractive to pharmaceutical companies. The siRNA modality offers advantages such as infrequent dosing and strong target engagement, which could overcome limitations of existing treatments.
Moreover, the partnership with Sirius diversifies Crispr Therapeutics’ pipeline and increases the probability of success for its gene editing initiatives. SRSD107’s potential to target large indications, starting with smaller ones like VTE prevention, without a significant increase in operating expenses, adds to its appeal. The company’s diversified pipeline, including upcoming launches and second-generation products, further supports the Buy rating, as these elements provide significant optionality and potential for future growth.

According to TipRanks, Biliouris is an analyst with an average return of -17.7% and a 26.09% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Crispr Therapeutics AG, and BioMarin Pharmaceutical.

In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $105.00 price target.